| Přispěvatelé: |
Instituto de Salud Carlos III, [Macías,J, Pinilla,A, Corma,A, González-Serna,A, Fernández-Fuertes,M, Trigo,M, Real,LM, Pineda,JA] Infectious Diseases and Microbiology Unit, Hospital Universitario Virgen de Valme, Seville, Spain. [Lao-Dominguez,FA, Contreras-Macias,E, Gutierrez-Pizarraya,A, Morillo-Verdugo,R] Pharmacy, Hospital Universitario Virgen de Valme, Seville, Spain. |
| Popis: |
The impact of drug–drug interactions (DDI) between ritonavir-boosted lopinavir (LPV-r) to treat patients with coronavirus disease 2019 (COVID-19) and commonly used drugs in clinical practice is not well-known. Thus, we evaluated the rate and severity of DDI between LPV-r for COVID-19 treatment and concomitant medications. This was a cross-sectional study including all individuals diagnosed of SARS-CoV-2 infection treated with LPV-r and attended at a single center in Southern Spain (March 1st to April 30th, 2020). The frequency [95% confidence interval (95% CI)] of potential and major DDI were calculated. Overall, 469 patients were diagnosed of COVID-19, 125 (27%) of them were prescribed LPV-r. LPV-r had potential DDI with concomitant medications in 97 (78%, 95% CI 69–85%) patients, and in 33 (26%, 95% CI 19–35%) individuals showed major DDI. Twelve (36%) patients with major DDI and 14 (15%) individuals without major DDI died (p = 0.010). After adjustment, only the Charlson index was independently associated with death [adjusted OR (95% CI) for Charlson index ≥ 5: 85 (10–731), p
This study has not been funded. J.A.P. is recipient of an intensification grant from the Instituto de Salud Carlos III (Grant number Programa-I3SNS). |
